Faeth Therapeutics Q2 FY26 net loss widens to $16.01 million
FTH•Clinical trial updates
The company said the first patient was dosed in the Phase 1b/2 PIK-101 trial in HR+/HER2- advanced breast cancer in April.
Topline data from the Phase 2 PIK-201 endometrial cancer trial are expected by year-end, and initial PIK-101 safety and efficacy data are expected in 2027.
Quarterly results and cash position
Faeth Therapeutics posted a net loss of $16.01 million, or $2.84 per share, for the quarter ended June 30, 2026.
- R&D expense more than doubled to $9.18 million.
- G&A expense more than doubled to $9.21 million.
- Cash, cash equivalents, and marketable securities climbed to $186.4 million as of June 30, 2026.
